To identify influence of different therapeutic and prognostic factors on survival, a review of the data on treatment of 197 patients with inflammatory breast cancer was carried out at the Dispensary (1994-2004). Multimodal treatment included combinations of radiotherapy, mastectomy and chemotherapy (CMF--75; CAF--98 and taxanes--9). Significantly lower survival was reported for patients with lymph node involvement (N1, N2 and N3) and those without mastectomy and radiotherapy. Overall 10-year survival was registered only in those who had received chemotherapy, radiotherapy and mastectomy (20.2% +/- 5.5); overall 5-year survival was 42.0% +/- 4.8.
Inflammatory breast cancer can be difficult to diagnose. Often, there is no lump that can be felt during a physical exam or seen in a screening mammogram. In addition, most women diagnosed with inflammatory breast cancer have dense breast tissue, which makes cancer detection in a screening mammogram more difficult. Also, because inflammatory breast cancer is so aggressive, it can arise between scheduled screening mammograms and progress quickly. The symptoms of inflammatory breast cancer may be mistaken for those of mastitis, which is an infection of the breast, or another form of locally advanced breast cancer.
The symptoms of inflammatory breast cancer may be mistaken for those of mastitis, which is an infection of the breast, or another form of locally advanced breast cancer.To help prevent delays in diagnosis and in choosing the best course of treatment, an international panel of experts published guidelines on how doctors can diagnose and stage inflammatory breast cancer correctly. Their recommendations are summarized below.